US2018344701A1PendingUtilityA1
Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
Assignee: UNIV VIRGINIA PATENT FOUNDATIONPriority: Sep 9, 2011Filed: Dec 20, 2017Published: Dec 6, 2018
Est. expirySep 9, 2031(~5.1 yrs left)· nominal 20-yr term from priority
Inventors:Bankole A. Johnson
A61K 31/4178C12Q 2600/106C12Q 2600/156A61P 25/30C12Q 1/6883
67
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides compositions and methods useful for diagnosing, treating, and monitoring alcohol dependence and disorders and susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating an addictive disease or disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of an antagonist of the serotonin receptor 5-HT 3 , wherein the patient's serotonin transporter gene SLC6A4 is known to have a genotype selected from sets (a)-(q):
(a.) the AA genotype of rs1176719 and the AG genotype of rs1150226; (b.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942; (c.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; (d.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; (e.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; (f.) the AA genotype of rs1176719 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; (g.) the AA genotype of rs1176719 and the GG genotype of rs1176713; (h.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; (i.) the AA genotype of rs1176719 and the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; (j.) the GG genotype of rs1176713 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; (k.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; (l.) the GG genotype of rs1176713 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; (m.) the GG genotype of rs1176713 and the AG genotype of rs1150226 and the AC genotype of rs17614942 and the LL genotype of 5-HTTLPR, and the TT genotype of rs1042173; (n.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713; (o.) the AG genotype of rs1150226 and the AA genotype of rs1176719 and the GG genotype of rs1176713; (p.) the AG genotype of rs1150226 and the AC genotype of rs17614942 and the GG genotype of rs1176713; and, (q.) the AA genotype of rs1176719 and the AC genotype of rs17614942 and the GG genotype of rs1176713.Join the waitlist — get patent alerts
Track US2018344701A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.